Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Hashemi, Mohammad; Bahari, Gholamreza; Markowski, Jarosław; Małecki, Andrzej; Łos, Marek; Ghavami, Saeid

doi:10.18632/oncotarget.25324

Cited by 10 publications

(9 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The random-effects model was used to estimate pooled ORs when heterogeneity values were significant. Z-test was performed to evaluate the significance of the pooled OR and p<0.05 was considered to be statistically significant (Hashemi et al, 2018). Publication bias was appraised using Begg's funnel plot.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 12 case-control studies were included in this meta-analysis to find out the association of TP53 codon 72 Arg/Pro polymorphism with lung cancer and breast cancer in the South Asian population based on the inclusion criteria (Shabnaz et al, 2016;Hashemi et al, 2018;Aziz et al, 2013;Suresh et al, 2011;Syeed et al, 2010;Ihsan et al, 2011;Tilak et al, 2013;Chowdhury et al, 2015;Mostaid et al, 2014;Saikia et al, 2014;Sharma et al, 2014). Among these, six studies evaluated the association for breast cancer (950 cases and 882 controls) and the other six studies for lung cancer (975 cases and 1,397 controls).…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis

Jafrin

Aziz

Anonna

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: A transversion missense polymorphism of the TP53 tumor suppressor gene at the codon 72 codes proline instead of arginine causes an altered p53 protein expression and has been found to be associated with an elevated risk of various cancer; especially breast and lung cancer. As the previous case-control studies on the South Asian population have shown controversial results, we performed a meta-analysis to evaluate a precise estimation of the relationship between the TP53 Arg72Pro polymorphism with breast and lung cancer. Methods: A total of 12 related studies on the South Asian population have been included through comprehensive database searching. Six studies were selected for breast cancer meta-analysis involving 950 cases and 882 controls; the other six studies were for lung cancer meta-analysis including 975 cases and 1397 controls. The results have been determined by using the Review Manager (RevMan) 5.3. Additionally, the stability of our analysis was assessed by heterogeneity, publication bias analysis and sensitivity testing. Results: A significantly increased risk of breast cancer was found in Pro allele (Pro vs. Arg), co-dominant model 2 (Pro/Pro vs. Arg/Arg), dominant model (Pro/Pro + Arg/Pro vs. Arg/Arg). In case of lung cancer, significantly increased risk was found in the allele, co-dominant 1, co-dominant 2, co-dominant 3, dominant, and recessive models. No association with other genetic models with breast and lung cancer risk was found in the South Asian population. Conclusions: Our results indicate that TP53 Arg72Pro polymorphism is a risk factor for the development of breast cancer and lung cancer in the South Asian population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis

Jafrin

Aziz

Anonna

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…BUB3 could play an important role in the control of the cell cycle and recurrence in prostate cancer 54 as the checkpoint of kinetochore–microtubule attachment could be impaired due to the observed decrease of this protein, required for the establishment of the mentioned protein complex 54 . PDCD6 has been reported to be upregulated in tumor tissue samples from lung, breast, colon cancer, and ovarian cancers and is involved in maintenance of cellular viability 55 . Different levels between recurrent and nonrecurrent samples in metabolite interconversion enzymes could potentially be explained by metabolic impairment that impacts cancer cells 56 .…”

Section: Discussionmentioning

confidence: 99%

Protein signatures to distinguish aggressive from indolent prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background Distinguishing men with aggressive from indolent prostate cancer is critical to decisions in the management of clinically localized prostate cancer. Molecular signatures of aggressive disease could help men overcome this major clinical challenge by reducing unnecessary treatment and allowing more appropriate treatment of aggressive disease. Methods We performed a mass spectrometry‐based proteomic analysis of normal and malignant prostate tissues from 22 men who underwent surgery for prostate cancer. Prostate cancer samples included Grade Groups (3–5), with 8 patients experiencing recurrence and 14 without evidence of recurrence with a mean of 6.8 years of follow‐up. To better understand the biological pathways underlying prostate cancer aggressiveness, we performed a systems biology analysis and gene enrichment analysis. Proteins that distinguished recurrent from nonrecurrent cancer were chosen for validation by immunohistochemical analysis on tissue microarrays containing samples from a larger cohort of patients with recurrent and nonrecurrent prostate cancer. Results In all, 24,037 unique peptides (false discovery rate < 1%) corresponding to 3,313 distinct proteins were identified with absolute abundance ranges spanning seven orders of magnitude. Of these proteins, 115 showed significantly (p < 0.01) different levels in tissues from recurrent versus nonrecurrent cancers. Analysis of all differentially expressed proteins in recurrent and nonrecurrent cases identified several protein networks, most prominently one in which approximately 24% of the proteins in the network were regulated by the YY1 transcription factor (adjusted p < 0.001). Strong immunohistochemical staining levels of three differentially expressed proteins, POSTN, CALR, and CTSD, on a tissue microarray validated their association with shorter patient survival. Conclusions The protein signatures identified could improve understanding of the molecular drivers of aggressive prostate cancer and be used as candidate prognostic biomarkers.

show abstract

“…Remaining two genes implicated in UBC and NMIBC survival, namely EGFR and PDCD6 , are both well-known cancer genes (14, 23). PDCD6 seems to be heavily involved in apoptosis (14); however, the exact role of PDCD6 is contrasting between various cancers (24), and further molecular research will help making evidence-based interpretations.…”

Section: Discussionmentioning

confidence: 99%

External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank

et al. 2019

View full text Add to dashboard Cite

Introduction: Multiple studies have reported genetic associations with prognostic outcomes of urinary bladder cancer. However, the lack of replication of these associations prohibits establishing further evidence-based research directions. Moreover, there is a lack of independent bladder cancer patient samples that contain prognostic measures, making genetic replication analyses even more challenging.Materials and Methods: We have identified 1,534 eligible patients and used data on Hospital Episode Statistics in the UK Biobank to model variables of otherwise non-collected events on bladder cancer recurrence and progression. Data on survival was extracted from the Death Registry. We have used SNPTEST software to replicate previously reported genetic associations with bladder cancer recurrence (N = 69), progression (N = 23), survival (N = 53), and age at the time of diagnosis (N = 20).Results: Using our algorithm, we have identified 618 recurrence and 58 UBC progression events. In total, there were 209 deaths (106 UBC-specific). In replication analyses, eight SNPs have reached nominal statistical significance (p < 0.05). Rs2042329 (CWC27) for UBC recurrence; rs804256, rs4639, and rs804276 (in/close to NEIL2) for NMIBC recurrence; rs2293347 (EGFR) for UBC OS; rs3756712 (PDCD6) for NMIBC OS; rs2344673 (RGS5) for MIBC OS, and rs2297518 (NOS2) for UBC progression. However, none have remained significant after adjustments for multiple comparisons.Discussion: External replication in genetic epidemiology is an essential step to identify credible findings. In our study, we identify potential genetic targets of higher interest for UBC prognosis. In addition, we propose an algorithm for identifying UBC recurrence and progression using routinely-collected data on patient interventions.

show abstract

Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Cited by 10 publications

References 44 publications

Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis

Association of TP53 Codon 72 Arg>Pro Polymorphism with Breast and Lung Cancer Risk in the South Asian Population: A Meta-Analysis

Protein signatures to distinguish aggressive from indolent prostate cancer

External Replication of Urinary Bladder Cancer Prognostic Polymorphisms in the UK Biobank

Contact Info

Product

Resources

About